STOCK TITAN
  1. Home
  2. News
  3. NBTX

Nanobiotix S.A. American Depositary Shares - NBTX STOCK NEWS

Welcome to our dedicated page for Nanobiotix S.A. American Depositary Shares news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. American Depositary Shares stock.

Nanobiotix S.A. (Euronext: NANO / ISIN: FR0011341205) is a leading clinical-stage nanomedicine company specializing in the development of groundbreaking approaches for cancer treatment. The company's core technology, NanoXray, augments the effectiveness of radiotherapy, offering a more efficient treatment option for cancer patients. The innovative NanoXray products are designed to be compatible with existing radiotherapy treatments and aim to treat a broad spectrum of solid tumors, such as soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma.

The primary product candidate, NBTXR3, is currently undergoing evaluation for its efficacy in treating soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers (both primary and metastases). Additionally, Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer in the Asia Pacific region.

Nanobiotix has also embarked on a preclinical research program in immuno-oncology, further expanding its portfolio and potential for transformative cancer therapies. NBTXR3 works by magnifying the effects of radiotherapy within tumor cells, thereby enhancing cancer treatment without increasing the dose to surrounding healthy tissues.

Recently, Nanobiotix has been focused on validating the safety and efficacy of RT-activated NBTXR3 by moving to global registration for LA-HNSCC, accounting for the majority of its operational and financial resources. The company plans to provide an updated global development plan for NBTXR3 after further alignment with the Joint Steering Committee (JSC).

In terms of financial performance, Nanobiotix has laid out a cautious strategy, ensuring that it remains well-funded to support ongoing and future operations. Their forward-looking statements highlight the potential risks and uncertainties that could affect their business and financial performance.

For the latest updates, Nanobiotix has scheduled a conference call and webcast on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST. It continues to engage the market, providing transparency to shareholders through various media and regular updates on their progress and milestones.

To keep up with the latest news, visit www.nanobiotix.com.

News

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.

Rhea-AI Summary
Nanobiotix (NANO – NBTX) has received approximately €55.5 million (equivalent to approximately $58.7 million) in gross proceeds from a subscription by Johnson & Johnson Innovation, extending its cash runway into mid-2025. This includes a closing of a subscription for 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares (ADSs), for an aggregate amount of $4.8 million. The subscription by JJDC was conditioned upon the approval of the French Ministry of Economy. The Company intends to use the net proceeds from the placement for its working capital requirements until mid-2025, assuming the receipt of the first milestone payment from Janssen Pharmaceutica NV under the Company’s License Agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
none
-
News

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

Rhea-AI Summary
Nanobiotix (NANO –– NBTX) reports a $2.5 billion global licensing, co-development, and commercialization agreement for NBTXR3. The company presented promising data for NBTXR3 in head and neck cancer and locally advanced pancreatic cancer. They raised €50.9 million, successfully removed the EIB cash covenant, and have multiple clinical readouts over the next 18 months. The company's financial runway is extended into 2Q 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
earnings
-
News

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

Rhea-AI Summary
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX) will report its financial results for the third quarter of 2023 on November 13, 2023. A conference call and webcast are scheduled for November 14, 2023, at 8:00 AM ET / 2:00 PM CET. The call will include a review of operational progress, business activities, and the latest data presented at the 2023 Annual Congress of the European Society for Medical Oncology (ESMO).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
earnings
News

Voting Rights and Shares Capital of the Company

Rhea-AI Summary
Nanobiotix (NANO:FP) Announces Monthly Disclosure of Total Voting Rights and Shares Outstanding
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
News

NANOBIOTIX Announces Closing of Global Offering

Rhea-AI Summary
NANOBIOTIX (NANO: Euronext, NBTX: NASDAQ) closes global follow-on offering, raising approximately $53.8 million. The offering includes 3,786,907 ADS in the U.S. and 2,492,223 Ordinary Shares in Europe, with JJDC subscribing for $25.0 million of the Company's restricted ADSs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
-
News

NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M

Rhea-AI Summary
Nanobiotix, a biotechnology company focusing on cancer treatment, announces the availability of its listing prospectus approved by the French Financial Markets Authority. The company has raised approximately $50 million through two share capital increases, with qualified investors subscribing for $30 million and Johnson & Johnson Innovation subscribing for $20.2 million. The funds raised will bring Nanobiotix's gross proceeds to $55 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
none
News

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

Rhea-AI Summary
Nanobiotix, a late-clinical stage biotechnology company, has priced its global follow-on offering. The offering consists of 3,106,907 American Depositary Shares (ADSs) in the United States at $5.36 per ADS and 2,492,223 Ordinary Shares in Europe at €5.07 per share. The aggregate gross proceeds are expected to be approximately $55 million. Jefferies LLC, Leerink Partners, and Guggenheim are acting as global coordinators and joint bookrunners for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.01%
Tags
none
-
News

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

Rhea-AI Summary
Nanobiotix, a biotechnology company, is launching a $30 million global follow-on offering. The offering includes an offering of American Depositary Shares (ADSs) in the United States and an offering of Ordinary Shares to qualified investors in Europe. Johnson & Johnson Innovation is obligated to subscribe for $25 million of Ordinary Shares. The proceeds will be used to advance clinical trials, research and development, and other operating expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.01%
Tags
none
-
News

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Rhea-AI Summary
Nanobiotix presents updated data from two presentations at the 2023 Annual Congress of the European Society for Medical Oncology (ESMO)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
clinical trial
News

Voting Rights and Shares Capital of the Company

Rhea-AI Summary
Nanobiotix announces monthly publication of voting rights and shares
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
none

FAQ

What is the current stock price of Nanobiotix S.A. American Depositary Shares (NBTX)?

The current stock price of Nanobiotix S.A. American Depositary Shares (NBTX) is $3.83 as of November 21, 2024.

What is the market cap of Nanobiotix S.A. American Depositary Shares (NBTX)?

The market cap of Nanobiotix S.A. American Depositary Shares (NBTX) is approximately 182.0M.

What is Nanobiotix S.A. known for?

Nanobiotix S.A. specializes in developing nanomedicine technologies for enhancing the efficacy of radiotherapy in treating cancer.

What is NanoXray technology?

NanoXray technology is a proprietary innovation by Nanobiotix that enhances the energy of radiotherapy to provide more efficient cancer treatment.

What types of cancer does NBTXR3 target?

NBTXR3 targets a variety of solid tumors, including soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers.

Who is Nanobiotix partnered with in the Asia Pacific region?

Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer.

What recent projects are Nanobiotix involved in?

Nanobiotix is focused on validating the safety and efficacy of RT-activated NBTXR3 and moving towards global registration for LA-HNSCC.

When is the next conference call and webcast scheduled?

The next conference call and webcast is scheduled for May 22, 2024, at 8:00 am EDT / 2:00 pm CEST.

How does NBTXR3 enhance radiotherapy?

NBTXR3 magnifies the effect of radiotherapy within tumor cells while minimizing the radiation dose to surrounding healthy tissues.

What is the significance of Nanobiotix’s preclinical research program?

Nanobiotix's preclinical research program in immuno-oncology aims to expand the potential for innovative cancer therapies by leveraging their nanotechnology.

Where can I find more information about Nanobiotix?

For more information, visit Nanobiotix's official website at www.nanobiotix.com.

Stock NBTX logo
Nanobiotix S.A. American Depositary Shares

Nasdaq:NBTX

NBTX Rankings

#3935 Ranked by Market Cap
N/A Ranked by Dividends

NBTX Stock Data

181.97M
46.87M
13.54%
0.07%
Biotechnology
Healthcare
Link
United States of America
Paris